Pulmonary comorbidity in chronic lymphoproliferative diseases: realities of the problem in the Dnipro region
DOI:
https://doi.org/10.26641/2307-0404.2021.4.248090Ключові слова:
lymphoproliferative diseases, lymphoma, respiratory diseases, dyspneaАнотація
The prevalence of the chronic lymphoproliferative diseases is increasing worldwide with increase of the population age. It is known that the presence of comorbidities in such patients plays an important role in predicting treatment outcomes. The aim of the work was to study the prevalence and determine the structure of respiratory symptoms and comorbid pulmonary pathology in patients with chronic lymphoproliferative diseases (CLPD) in the Dnipro region of Ukraine. After analyzing 986 cards of inpatients of the hematology department, whose average age was 65 (56; 69) years, it was determined that 9.0% of patients had at least one chronic respiratory disease, the most common among which were chronic bronchitis, chronic obstructive pulmonary disease, as well as community-acquired pneumonia. Dyspnea and tachypnea are also common among patients with CLPD without established respiratory comorbidity, cardiovascular disease, or anemia. Based on the data obtained, we can recommend a study of the respiratory function and pulse oximetry, as well as a thorough collection of anamnesis of smoking and analysis of the results of chest computed tomography in all patients with CLPD in order to identify the possible cause of shortness of breath and establish the presence of respiratory comorbidity.
Посилання
Antomonov MYu. [Mathematical processing and analysis of biomedical data]. 2-e izd. Kyiv: Medinform; 2018. p. 579. Russian. Available from: https://www.olx.ua/.../antomonov-m-yu-monografya
Baunova TV, Gusarova OS, Avitesyan VN. [Komorbidnaya patologiya u patsientov s mnozhestvennoy mielomoy]. Forcipe. 2019. Russian. URL: https://cyberleninka.ru/article/n/komorbidnaya-patologiya-u-patsientov-s-mnozhestvennoy-mielomoy
Zatserkovnyi VI, Tishaiev IV, Demydov VK. [Research methodology]. 2017. Ukrainian.
Gashynova KYu, Kolisnyk NS, Dmytrychenko VV, et al. [Invasive pulmonary aspergillosis: the state of art and the clinical case]. Medicni perspektivi. 2018:1(1):27-37. Ukrainian. doi: https://doi.org/10.26641/2307-0404.2018.1(part1).127204
Gasparini VR, Binatti A, Coppe A, et al. A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. Blood Cancer J. 2020;10(42):1-11. doi: https://doi.org/10.1038/s41408-020-0309-2
Shanafelt TD, Rabe KG, Kay J, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116:4777-87.
Rusu RA, Sîrbu D, Curşeu D, et al. Chemotherapy-related infectious complications in patients with Hematologic malignancies. J Res Med Sci. 2018;23:68. doi: https://doi.org/10.4103/jrms.JRMS_960_17
Visentin A, et al. Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematol Oncol. 2017;35(4):925-8. doi: https://doi.org/10.1002/hon.2343
Glimelius I, Diepstra A. Novel treatment concepts in Hodgkin lymphoma. J Intern Med. 2017;281:247-60. doi: https://doi.org/10.1111/joim.12582
Cowan AJ, Allen C, Barac A, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221-7. doi: https://doi.org/10.1001/jamaoncol.2018.2128
Strugov V, Stadnik E, Virts Y, et al. Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia. Ann Hematol. 2018;97(11):2153-2161. doi: https://doi.org/10.1007/s00277-018-3409-3. Epub 2018 Jun 26. PMID: 29946909.
Goede V. et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: trial results of the German CLL Study Group. Haematologica. 2014;99(6):1095-100. doi: https://doi.org/10.3324/haematol.2013.096792
Facchinelli D, Marchesini G, Nadali G, Pagano L. Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs. Mediterr J Hematol Infect Dis. 2018;10(1):e2018063. doi: https://doi.org/10.4084/MJHID.2018.063
Strati P, et al. Relationship between co‐morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178:394-402. doi: https://doi.org/10.1111/bjh.14785
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, based on November 2019 SEER data submission, posted to the SEER web site, April 2020. Available from: https://seer.cancer.gov/csr/1975_2017/
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2021 Медичні перспективи
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
